Spotlight Innovation Subsidiary Celtic Biotech Enters Into Research Agreement With Emory University
Marketwired - Mon Jul 06, 12:43PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has entered into a Research Agreement with Atlanta-based Emory University. The Phase I study will be designed and conducted by an Emory University research team with the specific aim of demonstrating that the cell penetrating peptide Crotamine can be made into a suitable radiopharmaceutical for imaging lung cancer tumors with positron emission tomography (PET) in a clinical setting.
Spotlight Innovation Retains DresnerAllenCaron as Its Investor Relations Firm
Marketwired - Thu Jun 18, 10:51AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has retained DresnerAllenCaron as its investor relations firm. DresnerAllenCaron will design and execute investor relations programs to broaden awareness and visibility of Spotlight Innovation within the investment community, and the business and financial media.
Spotlight Innovation Completes Acquisition of Memcine Pharmaceuticals
Marketwired - Mon Jun 08, 9:45AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.
Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities
Marketwired - Tue Jun 02, 2:31PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. FreeMind Group's expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation Becomes Member of Iowa Biotechnology Association
Marketwired - Tue May 12, 12:19PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has become a member of the Iowa Biotechnology Association. The Association was founded to unify Iowa's bioscience industry, academic research institutions and economic development organizations, and to foster a strong business and research climate that attracts and retains bioscience talent, companies and funding.
Spotlight Innovation Closes $2.5 Million Financing
Marketwired - Tue Apr 28, 12:05PM CDT
Spotlight Innovation Inc. (the "Company"
Spotlight Innovation Completes Private Placement Offering of $500,000
Marketwired - Tue Apr 21, 1:25PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
Spotlight Innovation Subsidiary Celtic Biotech Product EPISORB Available to Compounding Pharmacy Industry
Marketwired - Mon Apr 06, 12:44PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals
Marketwired - Tue Mar 17, 12:50PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals. The closing of the transaction is contingent upon several conditions including, but not limited to, completion of due diligence and entry into a shareholder agreement.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease
Marketwired - Tue Mar 10, 2:46PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office
Marketwired - Thu Jan 15, 1:22PM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Spotlight Innovation Signs Memorandum of Understanding (MOU) With Black Swan LLC
Marketwired - Tue Jan 06, 10:01AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Spotlight Innovation Announces Change of Transfer Agent
Marketwired - Tue Dec 16, 8:03AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces today that effective December 16, 2014, Spotlight Innovation is replacing Securities Transfer Corporation as the transfer agent and registrar of the securities of the Company.
Celtic Biotech Iowa Requests Reactivation and Transfer of National Drug Code Registration
Marketwired - Thu Dec 04, 9:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product. The novel gel formula, originally developed by scientists at Celtic Biotech to facilitate the topical delivery of its proprietary biologic analgesic and anti-inflammatory drugs, is designed to provide a convenient platform for the compounding pharmacy industry to prepare and effectively deliver topical pain medications.
Spotlight Innovation Signs Letter of Intent to Acquire Memcine Pharmaceuticals
Marketwired - Tue Oct 14, 3:51PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Spotlight Innovation Retains Jerry Cirino as Special Advisor
ACCESSWIRE - Wed Oct 01, 1:21PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
ACCESSWIRE - Wed Sep 24, 1:04PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg